Entering text into the input field will update the search result below

Pharmacyclics' (PCYC +1.7%) Phase III trial of its ibrutinib drug for treating leukiemia has...

Aug. 01, 2012 10:21 AM ETPharmacyclics, Inc. (PCYC) StockJNJ, PCYCBy: Yigal Grayeff, SA News Editor

Pharmacyclics' (PCYC +1.7%) Phase III trial of its ibrutinib drug for treating leukiemia has enrolled a 5th patient, thereby triggering a milestone payment of $50M from J&J (NYSE:JNJ) unit Janssen Biotech. Additional $50M payments could be triggered up to a total of $250M. (PR)

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
PCYC--
Pharmacyclics, Inc.